Published: 22 May 2020
Author(s): Corrado Campochiaro, Emanuel Della-Torre, Giulio Cavalli, Giacomo De Luca, Marco Ripa, Nicola Boffini, Alessandro Tomelleri, Elena Baldissera, Patrizia Rovere-Querini, Annalisa Ruggeri, Giacomo Monti, Francesco De Cobelli, Alberto Zangrillo, Moreno Tresoldi, Antonella Castagna, Lorenzo Dagna, TOCI-RAF Study Group
Issue: May 2020
Section: Original article

Starting from December 2019, the World has faced a global pandemic of a novel coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. As of May 2nd, 2020, the pandemic has affected more than 3.400.000 people worldwide [2]. The Lombardy region in Italy has become the epicentre of the European COVID-19 outbreak, and an exponential surge in COVID-19 patients posed a critical burden on the National Health System [3, 4]. To date, no pharmacologic therapy has been approved for the treatment of COVID-19.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.